The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
Conclusion: The AEs associated with CDK4/6 inhibitors vary, necessitating individualized and precise clinical selection for optimal management. This approach should be based on the patient’s medical history and the distinct characteristics of different CDK4/6 inhibitors to improve the patient’s quality of life.Systematic Review Registration: [https://systematicreview.gov/], identifier [CRD42022350167]
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Alopecia | Anemia | Breast Cancer | Cancer | Cancer & Oncology | Constipation | Cough | Databases & Libraries | Drugs & Pharmacology | Endocrine Therapy | Hematology | HER2 | Pain | Pain Management | Science | Thrombocytopenia | Thrombosis | Toxicology